OSN’s top news of the week

Here are the top stories of the past week on Healio.com/OSN:
Dexycu receives permanent J-code
Dexycu (dexamethasone intraocular suspension) 9%, the first FDA-approved, single-dose, sustained-release intracameral steroid for the treatment of postoperative inflammation, will have the code J1095. Read more.
Zimura-Lucentis combination safe in wet AMD patients in phase 2a trial
Zimura, a complement factor C5 inhibitor, was found to be well tolerated in combination with Lucentis in a phase 2a clinical trial. Read more.
Mazzo, SEC settle insider trading case
James V. Mazzo, who formerly

Full Story →